Related Experiment Videos
Overview of postmarketing experience with ofloxacin in Germany
Abstract:
Clinical trials with ofloxacin have shown that adverse drug events (ADEs) occurred in between 2.4% (Phase II) and 3.1-7.3% (Phase IV) of patients treated and were mostly mild. As with any other drug the true spectrum of rare events can only be fully appreciated after marketing. Since the launch of ofloxacin in June 1985 about 3.5 million patients have been treated in Germany, calculated on the basis of a mean daily dose of 400 mg ofloxacin and a mean duration of treatment of seven days. During these 2.5 years 985 spontaneous national reports of ADEs have been obtained and include rare adverse events (e.g. hallucination, psychotic reaction and shock), not seen in clinical trials. The present status of results from postmarketing surveillance is shown and discussed. The favourable overall risk:benefit ratio of ofloxacin appears unchanged.
Insights
Postmarketing surveillance of ofloxacin in Germany revealed rare adverse drug events (ADEs) not seen in clinical trials. The drug
Area of Science:
- Pharmacovigilance
- Clinical Pharmacology
Background:
- Clinical trials for ofloxacin indicated a low incidence of mild adverse drug events (ADEs).
- Postmarketing surveillance is crucial for identifying rare adverse events not detected during clinical trials.
Purpose of the Study:
- To present the status of results from postmarketing surveillance of ofloxacin.
- To evaluate the safety profile of ofloxacin after its market launch.
Main Methods:
- Analysis of 985 spontaneous national reports of ADEs over 2.5 years post-ofloxacin launch in Germany.
- Calculation based on approximately 3.5 million patients treated with a mean daily dose of 400 mg for seven days.
Main Results:
- Rare adverse events, including hallucination, psychotic reaction, and shock, were reported.
- These rare events were not observed in pre-marketing clinical trials.
- The overall risk:benefit ratio of ofloxacin remained favorable.
Conclusions:
- Postmarketing surveillance identified rare adverse events associated with ofloxacin.
- The favorable risk:benefit profile of ofloxacin is maintained despite the identification of rare ADEs.